Back

Radiopharm reports positive Phase 1 imaging data for pancreatic cancer drug RAD301

Verifying
  • Radiopharm reported Phase 1 safety and imaging results for RAD301 in pancreatic cancer.
  • All evaluable participants showed favorable safety, while metastases demonstrated significant and selective tumor uptake.
  • RAD301 received FDA Orphan Drug Designation before the company announced these results.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Radiopharm reports positive Phase 1 imaging data for pancreatic cancer drug RAD301 - CoinPost Terminal